The ESMO GI 2025 Congress brought together specialists from around the world in Barcelona from July 2 to 5 to…
Elena Élez
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies…
Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase…
Presented at ESMO Congress 2024, results from the phase 1b CodeBreaK study in patients with KRAS G12C-mutated metastatic colorectal cancer…
Announced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has…
Reported today during a Proffered Paper session at the ESMO Gastrointestinal Cancers Annual Congress (ESMO GI) 2024*, first health-related quality…
Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…
Results of the study FRESCO-2 show a statistically and clinically meaningful benefit with a favorable safety profile in patients with…
Published in The Lancet Oncology results of the multicenter phase II MOUNTAINEER study (1) show that tucatinib plus trastuzumab had…
